KPC Pharmaceuticals Inc banner

KPC Pharmaceuticals Inc
SSE:600422

Watchlist Manager
KPC Pharmaceuticals Inc Logo
KPC Pharmaceuticals Inc
SSE:600422
Watchlist
Price: 11.08 CNY -0.27% Market Closed
Market Cap: ¥8.4B

KPC Pharmaceuticals Inc's latest stock split occurred on May 9, 2016

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

Before the split, KPC Pharmaceuticals Inc traded at 29.13 per share. Afterward, the share price was about 12.2998.

The adjusted shares began trading on May 9, 2016. This was KPC Pharmaceuticals Inc's 3rd stock split, following the previous one in Apr 18, 2005.

Last Splits:
May 9, 2016
2-for-1
Apr 18, 2005
2-for-1
Jul 21, 2004
8-for-5
Pre-Split Price
12.8585 29.13
Post-Split Price
12.2998
Before
After
Last Splits:
May 9, 2016
2-for-1
Apr 18, 2005
2-for-1
Jul 21, 2004
8-for-5

KPC Pharmaceuticals Inc
Stock Splits History

KPC Pharmaceuticals Inc Stock Splits Timeline
May 9, 2016
May 9, 2016
Split 2-for-1
x2
Pre-Split Price
12.8585 29.13
Post-Split Price
12.2998
Before
After
Apr 18, 2005
Apr 18, 2005
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
7.0797
Before
After
Jul 21, 2004
Jul 21, 2004
Split 8-for-5
x1.6
Pre-Split Price
N/A
Post-Split Price
7.0797
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 24, 2026
Cue Biopharma Inc
NASDAQ:CUE
1-for-30
/30
0.5542 16.626 USD 17.695 17.695 USD
Apr 24, 2026
Medical Data Vision Co Ltd
TSE:3902
2-for-7253607
/3626803.5
1684 1684 JPY N/A
Apr 24, 2026
E
ESGL Holdings Ltd
NASDAQ:ESGL
1-for-3
/3
2.35 7.05 USD 2.93 2.93 USD
Apr 24, 2026
Metro Mining Ltd
ASX:MMI
1-for-20
/20
0.067 1.34 AUD 1.3 1.3 AUD
Apr 24, 2026
L
La Comer SAB de CV
OTC:LCMRF
115-for-114
x1.0087719298246
2.4715 2.4341 USD 2.45 2.45 USD
Load More

KPC Pharmaceuticals Inc
Glance View

KPC Pharmaceuticals Inc., founded in 1951, has cultivated a strong presence in the pharmaceutical industry, rooted in the rich herbal traditions of China. With its headquarters strategically located in Yunnan, a region renowned for its vast biodiversity, KPC leverages this unique advantage by integrating indigenous herbal knowledge into modern pharmaceuticals. The company has carved a niche for itself primarily through the production and distribution of traditional Chinese medicine. This approach not only honors the cultural heritage of its origins but also allows the company to capitalize on a growing global demand for alternative and complementary medical treatments. The blend of traditional herbal medicine and cutting-edge pharmaceutical practices forms the backbone of its business model, enabling KPC to sustain substantial revenue through both local and international markets. Diversification is a cornerstone of KPC Pharmaceuticals' strategy. Beyond its traditional medicines, the company has aggressively pursued research and development in the biopharmaceutical sector. This move has expanded its product offerings to include chemical drugs, biotechnology, and over-the-counter products, broadening their appeal to a more extensive clientele. The continuous investment in R&D has led to the development of innovative treatments for ailments such as cardiovascular diseases, cancer, and other chronic illnesses. Additionally, KPC's robust sales network encompasses hospitals, pharmacies, and other healthcare institutions, ensuring widespread distribution and accessibility of its products. Through this diversified portfolio and strong distribution channels, KPC Pharmaceuticals continues to thrive by meeting the evolving needs of the healthcare industry while maintaining its commitment to quality and efficiency.

Intrinsic Value
10.17 CNY
Overvaluation 8%
Intrinsic Value
Price ¥11.08
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett